You are currently viewing a new version of our website. To view the old version click .
Hematology Reports
  • Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
  • Article
  • Open Access

Published: 25 January 2013

Thrombotic Thrombocytopenic Purpura in a Patient with Interferon Treated Hepatitis C Successfully Treated with Rituximab

and
Division of Hematology/Oncology, Brookdale University Hospital Medical Center, Brooklyn, NY 11212, USA
*
Author to whom correspondence should be addressed.

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life threatening condition associated with formation of platelet thrombi. Deficiency of ADAM TS 13 with presence of inhibitory anti-ADAM TS 13 Immunoglobulin G antibody is seen in patients with acquired TTP. TTP in patients on interferon therapy for chronic hepatitis C has rarely been reported. Furthermore, successful treatment of an initial episode of acute refractory acquired TTP, in a patient of chronic hepatitis C during interferon therapy with Rituximab, has not been previously reported. Here we describe a case of acute refractory acquired TTP associated with pegylated interferon therapy for her chronic hepatitis C infection. Initially refractory to plasmapheresis and steroids, she was successfully treated with Rituximab and plasmaphersis without any evidence of reactivation of hepatitis.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.